Ono Pharmaceutical Co (MEX:4528N) Moat Score: 6/10 (As of Jul. 03, 2026)


MEX:4528N Ono Pharmaceutical Co Ltd MEX:4528N
87 GF Score
Price MXN341.69
GF Value MXN324.16
! 2 Warning Signs
View Full Analysis

What is Ono Pharmaceutical Co Moat Score?

Ono Pharmaceutical Co MEX:4528N 87 Moat Score is 6 as of Jul. 03, 2026. GuruFocus rates MEX:4528N with a GF Score™ of 87/100 and a GF Value™ of MXN324.16. The stock has 2 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Ono Pharmaceutical Co ranks better than 97.09% on this metric.

Ono Pharmaceutical Co has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Ono Pharmaceutical Co has Narrow Moat: Ono Pharmaceutical has a strong narrow moat due to its valuable patents and consistent R&D capabilities. It benefits from regulatory barriers and some pricing power, but faces competition from larger pharmaceutical companies.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ono Pharmaceutical Co might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Ono Pharmaceutical Co  (MEX:4528N) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ono Pharmaceutical Co Moat Score Related Terms

MEX:4528N vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ono Pharmaceutical Co Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's Moat Score falls into.


MEX:4528N
87GF Score
Ono Pharmaceutical Co Ltd MEX:4528N
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Ono Pharmaceutical Co (MEX:4528N) has a Moat Score of 6 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ono Pharmaceutical Co ranks #30 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Ono Pharmaceutical Co's Moat Score too high?
Ono Pharmaceutical Co's current Moat Score is 6. Based on the distribution chart, Ono Pharmaceutical Co ranks #30 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ono Pharmaceutical Co has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #30 out of 1032 companies for Moat Score. This places Ono Pharmaceutical Co in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Ono Pharmaceutical Co's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Ono Pharmaceutical Co (MEX:4528N) has a current Moat Score of 6. The stock's GF Value™ is MXN324.16, compared to a current price of MXN341.69 — trading 5.4% above its estimated fair value. The current Moat Score is 6. Ono Pharmaceutical Co's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ono Pharmaceutical Co (MEX:4528N), the current Moat Score is 6 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ono Pharmaceutical Co (MEX:4528N) Overvalued in 2026?

Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued. The current stock price of MXN341.69 is trading 5.4% above its estimated GF Value™ of MXN324.16.

Key valuation signals for MEX:4528N:

  • Moat Score: 6
  • GF Value™: MXN324.16 vs. price of MXN341.69 (5.4% above fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the MEX:4528N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ono Pharmaceutical Co Business Description

Address 1-8-2 Kyutarocho, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
87GF Score

Get the complete analysis for MEX:4528N

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN341.69
Price
MXN324.16
GF Value